KEIO UNIVERSITY
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1858-01-01
- Employees
- 1K
- Market Cap
- -
Clinical Trials
246
Active:0
Completed:126
Trial Phases
5 Phases
Phase 1:9
Phase 2:4
Phase 3:2
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (244 trials with phase data)• Click on a phase to view related trials
Not Applicable
221 (90.6%)Phase 1
9 (3.7%)Phase 4
8 (3.3%)Phase 2
4 (1.6%)Phase 3
2 (0.8%)Changes in MTX-PG Concentrations During Subcutaneous MTX Therapy in Patients With Rheumatoid Arthritis(COSMOS Study)
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Keio University
- Target Recruit Count
- 100
- Registration Number
- NCT06913907
- Locations
- 🇯🇵
Keio University Hospital, Shinjuku-ku, Tokyo, Japan
Enhanced Human Sensorimotor Integration Via Self-modulation of the Somatosensory Activity
Not Applicable
Completed
- Conditions
- Somatosensory Evoked Potentials, and Electroencephalography
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Keio University
- Target Recruit Count
- 39
- Registration Number
- NCT06814873
- Locations
- 🇯🇵
Keio University, Yokohama, Kanagawa, Japan
Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel
Phase 2
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: FLOT therapy
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Keio University
- Target Recruit Count
- 60
- Registration Number
- NCT04699994
- Locations
- 🇯🇵
Keio University Hospital, Tokyo, Japan
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Keio University
- Target Recruit Count
- 22
- Registration Number
- NCT04546074
- Locations
- 🇯🇵
Keio University Hospital, Shinjuku, Tokyo, Japan
Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Keio University
- Target Recruit Count
- 300
- Registration Number
- NCT03505008
- Locations
- 🇯🇵
Fujita Health University Hospital, Aichi, Japan
🇯🇵Chiba University Hospital, Chiba, Japan
🇯🇵Hiroshima University Hospital, Hiroshima, Japan
- Prev
- 1
- 2
- 3
- Next
News
Adipose-Derived Stem Cell Injections Show Promise in Treating Inflammatory Eye Diseases
Japanese researchers demonstrate that local injections of adipose-derived mesenchymal stem cells effectively reduce inflammation in ocular graft-versus-host disease, offering a safer alternative to corticosteroids.